All In Biotech

Drug Trial Radar · NCT03890666

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

333

Actual

Start

Oct 26, 2020

Primary completion

Oct 4, 2021

Study completion Oct 4, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health platform (DHP) (Cloud solution), and dashboard, to optimize outcomes in participants at least 13 years of age or older with asthma. The study will consist of a screening visit, a 12-week open-label treatment period, and a follow-up telephone call (2 weeks following treatment completion). Participants with suboptimal asthma control will be enrolled in the study and randomized in a 1:1 ratio to 1 of 2 parallel groups stratified by investigational center: DS group participants utilizing the Albuterol eMDPI DS, including inhaler, App, DHP (Cloud solution), and dashboard, and CC group participants who will be treated with their standard of care albuterol-administering rescue inhalers and will not use the DS during the treatment period.

Conditions

  • Asthma

Interventions

  • Albuterol eMDPI DSDrug

    Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) DS with 4 component devices: * Device 1: Albuterol eMDPI * Device 2: Albuterol eMDPI Patient-facing smart device application (App) * Device 3: DHP Cloud solution) * Device 4: Provider-facing dashboard (dashboard)

  • albuterolDrug

    Standard of care albuterol-administering rescue inhaler

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Meaningful Asthma Improvement at the End of 12-Week Treatment PeriodTime frame: Baseline to Week 12

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 14232

    Birmingham, Alabama

  • Teva Investigational Site 14302

    Los Angeles, California

  • Teva Investigational Site 14301

    Stockton, California

  • Teva Investigational Site 14236

    Colorado Springs, Colorado

  • Teva Investigational Site 14198

    Denver, Colorado

  • Teva Investigational Site 14220

    New Haven, Connecticut

  • Teva Investigational Site 14197

    Aventura, Florida

  • Teva Investigational Site 14306

    Miami, Florida

  • Teva Investigational Site 14215

    Sarasota, Florida

  • Teva Investigational Site 14304

    Albany, Georgia

  • Teva Investigational Site 14195

    Savannah, Georgia

  • Teva Investigational Site 14217

    Evanston, Illinois

  • Teva Investigational Site 14218

    Springfield, Illinois

  • Teva Investigational Site 14305

    Louisville, Kentucky

  • Teva Investigational Site 14191

    Owensboro, Kentucky

  • Teva Investigational Site 14233

    Ann Arbor, Michigan

  • Teva Investigational Site 14207

    Bellevue, Nebraska

  • Teva Investigational Site 14221

    New York, New York

  • Teva Investigational Site 14234

    Chapel Hill, North Carolina

  • Teva Investigational Site 14187

    Cincinnati, Ohio

  • Teva Investigational Site 14210

    Philadelphia, Pennsylvania

  • Teva Investigational Site 14208

    Pittsburgh, Pennsylvania

  • Teva Investigational Site 14200

    Providence, Rhode Island

  • Teva Investigational Site 14300

    Charleston, South Carolina

  • Teva Investigational Site 14196

    Greenville, South Carolina

  • Teva Investigational Site 14188

    San Antonio, Texas

  • Teva Investigational Site 14192

    San Antonio, Texas

  • Teva Investigational Site 14189

    San Antonio, Texas

  • Teva Investigational Site 14190

    Greenfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.